Aphria (NYSE:APHA) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Aphria (NYSE:APHA) in a report issued on Tuesday morning, Briefing.com Automated Import reports. The firm issued an overweight rating and a $10.40 target price on the stock. Cantor Fitzgerald also issued estimates for Aphria’s FY2020 earnings at $0.00 EPS.

Other equities research analysts have also recently issued reports about the company. Zacks Investment Research raised Aphria from a hold rating to a buy rating and set a $5.50 price target on the stock in a report on Thursday, October 17th. CIBC reissued a sell rating and set a $6.50 price target on shares of Aphria in a report on Wednesday, October 16th. ValuEngine raised Aphria from a hold rating to a buy rating in a report on Thursday, August 1st. Jefferies Financial Group set a $8.30 price target on Aphria and gave the company a buy rating in a report on Tuesday, October 15th. Finally, Pi Financial set a $9.00 price target on Aphria and gave the company a buy rating in a report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $11.38.

APHA stock opened at $5.07 on Tuesday. The company has a market cap of $1.29 billion, a P/E ratio of -46.09 and a beta of 2.83. Aphria has a 1 year low of $3.75 and a 1 year high of $12.64. The stock’s fifty day moving average price is $5.22 and its 200-day moving average price is $6.35.

Aphria (NYSE:APHA) last released its earnings results on Tuesday, October 15th. The company reported $0.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.10. The company had revenue of $126.10 million for the quarter, compared to analysts’ expectations of $131.15 million. The company’s revenue was up 848.1% compared to the same quarter last year. Sell-side analysts expect that Aphria will post 0.05 earnings per share for the current year.

Hedge funds have recently modified their holdings of the company. Synovus Financial Corp increased its holdings in shares of Aphria by 56.9% in the second quarter. Synovus Financial Corp now owns 5,514 shares of the company’s stock worth $39,000 after purchasing an additional 2,000 shares during the last quarter. Liberty Wealth Management LLC bought a new stake in shares of Aphria in the second quarter worth about $44,000. Tower Research Capital LLC TRC increased its holdings in shares of Aphria by 76.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,248 shares of the company’s stock worth $44,000 after purchasing an additional 2,698 shares during the last quarter. Capital Investment Advisory Services LLC increased its holdings in shares of Aphria by 2,233.3% in the second quarter. Capital Investment Advisory Services LLC now owns 7,000 shares of the company’s stock worth $43,000 after purchasing an additional 6,700 shares during the last quarter. Finally, Lindbrook Capital LLC bought a new stake in shares of Aphria in the second quarter worth about $53,000. 10.94% of the stock is currently owned by hedge funds and other institutional investors.

About Aphria

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

Further Reading: What does the Dogs of the Dow mean?

Analyst Recommendations for Aphria (NYSE:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.